Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million Wednesday through the sale of 5.2 million shares

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE